Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation

• Tipo: Artigo em Revista Científica Internacional
• Data: 2017

Autores

Magro F (Autor) FMUP; Afonso, J (Autor) FMUP; Lopes, S (Autor) Outra; Coelho, R (Autor) Outra; Goncalves, R (Autor) Outra; Caldeira, P (Autor) Outra; Lago, P (Autor) Outra; de Sousa, HT (Autor) Outra; Ramos, J (Autor) Outra; Goncalves, AR (Autor) Outra; Ministro, P (Autor) Outra; Rosa, I (Autor) Outra; Vieira, AI (Autor) Outra; Andrade, P (Autor) Outra; Soares, JB (Autor) Outra; Carvalho, D (Autor) Outra; Sousa, P (Autor) Outra; Meira, T (Autor) Outra; Lopes, J (Autor) Outra; Moleiro, J (Autor) Outra; Dias C (Autor) FMUP; Falcao, A (Autor) Outra; Geboes, K (Autor) Outra; Carneiro F (Autor) FMUP

Revista

Título: EBioMedicine

Vol. 21

Páginas: 123-130

Editora: Elsevier

Indexação

ISI Web of Knowledge - 8 Citações

Scopus - 9 Citações

Outras Informações

ID Authenticus: P-00N-0GT

DOI: 10.1016/j.ebiom.2017.06.004

Abstract (EN): Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multicentric and prospective study involving 65 UC patients in the maintenance phase of IFX therapy. There were no significant differences between patients with positive and negative clinical, endoscopic and histological outcomes concerning their IFX trough levels (TLs), area under the IFX concentration vs. time curve (AUC), clearance and antibodies to infliximab (ATI) levels. However, the need to undergo therapeutic escalation later in disease development was significantly associated with higher ATI levels (2.62 mu g/mL vs. 1.15 mu g/mL, p=0.028). Moreover, and after adjusting for disease severity, the HR (hazard ratio) for therapeutic escalation was significantly decreased for patients with an ATI concentration below 3 mu g/mL (HR = 0.119, p = 0.010), and increased for patients with fecal calprotectin (FC) level above 250 mu g/g (HR = 9.309, p = 0.018). In clinically-stable UC patients, IFX pharmacokinetic features cannot predict therapeutic response on a short-term basis. However, high levels of ATIs or FC may be indicative of a future therapeutic escalation. (C) 2017 The Authors. Published by Elsevier B.V.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 8